FundedIQ
Health Care

PLAIO

PLAIO is a web-based SaaS platform intended to help generic pharmaceutical companies to digitize their demand, manufacturing, and purchase planning.PLAIO offers features like visual and capacity planning, advanced constraint/overhead calculations.

plaio.io Reykjavík, Iceland 1-10 employees
Total raised
$2.3M
Rounds
1
Latest
Seed
Dec 2021

PLAIO is a web-based SaaS platform intended to help generic pharmaceutical companies to digitize their demand, manufacturing, and purchase planning.PLAIO offers features like visual and capacity planning, advanced constraint/overhead calculations.

PLAIO has raised $2.3M across 1 round. Its most recent round was a Seed of $2.3M in Dec 2021. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Dec 15, 2021
Seed
$2.3M

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

PLAIO is featured in

Similar companies

PLAIO

PLAIO is an online software as a service tool designed for generic pharmaceutical companies to streamline their demand, manufacturing, and purchasing planning. It includes visual and capacity planning features, as well as advanced calculations for constraints and overhead costs.

Seed $4.7M
Kerecis

Kerecis creates licensed fish-skin items to mend the human body. Since no sickness move risk exists between chilly water fish and people, the Kerecis fish skin is just delicately handled and holds its closeness to human skin, making it an optimal substitute for human skin. In excess of 50 examinations have been finished on Kerecis innovation. Those reviews incorporate two twofold visually impaired, near, randomized control preliminaries, where fish skin treatment was more solid than mammalian-based medicines. Kerecis is likewise creating items for regions like oral medical procedure, plastic medical procedure, and neurological applications. The organization's items use various licensed unsaturated fat advancements to secure and recover tissue across two center innovations like Kerecis Omega3 Fish Skin and Kerecis Omega3 Viruxide.

Venture - Series Unknown $50.0M
Sidekick Health

Sidekick is a patient-centric digital care platform that is scalable across a wide range of chronic illnesses. It delivers industry-leading retention and clinical impact on health outcomes including cardiovascular fitness, weight, blood glucose, quality of life, fatigue, and medication adherence. The Sidekick platform combines an evidence-based clinical approach with behavioral economics and gamification. It helps global customers like Pfizer and Bayer expand therapy reach and impact across multiple therapeutic areas and diseases, operating in multiple countries. The platform is a CE-marked, Class I Medical Device.

Series B $55.0M
EpiEndo Pharmaceuticals

EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the enhancement of epithelial barrier integrity as a causal pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human skin and lung tissue, as well as the intestinal tract and genitalia. Compromised integrity of this barrier is implicated in the progression and non-resolution of inflammation. EpiEndo is developing a proprietary portfolio of orally available macrolide drug candidates with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic respiratory diseases and other significant unmet medical needs. EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral, disease modifying, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for COPD and other inflammatory airway diseases.

Series A $23.4M
Intellihealth

Intellihealth creates medical technology software that aids in diagnosing diseases associated with obesity. One of the company's primary offerings, Evolve, allows healthcare professionals to provide effective obesity treatment to patients, whether through telehealth or in-person consultations.

Venture - Series Unknown $5.2M
Ember Copilot

Ember Copilot is a Software Development firm offering a tool to reduces medical claim denials.

Seed $4.3M
Reimagine Care

Reimagine Care is a health care company that provides technology-enabled services to support community-based oncology care settings. It aims to make high-quality cancer care more affordable, accessible, and patient-centric. Reimagine Care partners with HC systems and independent physician oncology practices to support value-based oncology care delivery in the community. They do this by providing the people, processes, and a robust technology platform that enables the scalable and effective delivery of high-quality, patient-centric, lower-cost cancer care across multiple care sites, including the home. It was founded in 2020 and is based in Nashville, Tennessee.

Venture - Series Unknown $2.4M
QSimulate

QSimulate is currently hiring for various positions such as scientists, software engineers, project managers, and business development, as the team expands. Our office locations include Boston MA, Berkeley CA, and Ghent, Belgium. Remote options are also considered for technical roles. For further details, please contact us at info@qsimulate.com.

Seed
Function Health

100 Healthy Years • Your new routine of 120+ advanced lab tests explained by the world's top doctors

Series B $298M
Perelel

Perelel is a supplement manufacturer designed for various stages of a woman's reproductive life cycle.

Private Equity $27.0M
House Rx

House Rx is a health technology platform focused on improving affordability and patient access to specialty medications.

Series B $55.0M
Saluda Medical

In 2013, Saluda Medical was founded with the objective of transforming four years of investigation from NICTA, a top-class information communications technology hub in Australia, into a profitable endeavor. The personnel of the firm comprises engineers, medical practitioners, and seasoned experts who have a track record of successfully launching medical technologies.

Venture - Series Unknown $30.0M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.